Current evidence is limited by small, mainly single-dose studies, predominantly Chinese populations, and the absence of validated exposure-response relationships integrating imrecoxib, M1, and M2, and the absence of validated exposure-response relationships integrating imrecoxib, M1, and M2.
Sheng-Nan Zhao, Charlie Li, Marlon C. Mallillin et al.· Clinical Pharmacokinetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.